A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Open-label, cohort study to determine the safety and tolerability of the combination of daily
niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.